Anzeige
Mehr »
Samstag, 18.10.2025 - Börsentäglich über 12.000 News
Denison erreicht neues 52 Wochen Hoch - Könnte ihr Joint Venture Partner Cosa der Nächste sein?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40Z30 | ISIN: US29970R3030 | Ticker-Symbol:
NASDAQ
17.10.25 | 21:59
6,890 US-Dollar
-28,23 % -2,710
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
EVAXION A/S ADR Chart 1 Jahr
5-Tage-Chart
EVAXION A/S ADR 5-Tage-Chart

Aktuelle News zur EVAXION Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrESMO: Evaxion hopes cancer vax data attracts partner after cash crunch forces smaller ph. 2 trial2
FrEvaxion A/S erhöht Grundkapital durch ADS-Verkäufe und Ausübung von Optionsscheinen2
FrEvaxion reports 75% response rate in melanoma vaccine trial3
FrEvaxion reports 75% Objective Response Rate in phase 2 trial with AI-designed personalized cancer vaccine EVX-0123875% Objective Response Rate as 12 out of 16 advanced melanoma patients had objective clinical responses, with 11 of the 12 responders continuing to respond at 24 months follow-upImmune activation observed...
► Artikel lesen
DiEvaxion A/S - 6-K, Report of foreign issuer2
MoEvaxion to present a breadth of data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025309Presentation will cover two-year clinical efficacy, immunogenicity and safety dataData will be presented at an oral session on October 17, 2025, followed by a webinar on October 22, 2025, providing...
► Artikel lesen
EVAXION Aktie jetzt für 0€ handeln
08.10.Evaxion expands AI-Immunology platform with automated vaccine design module277New platform module automates previous manual vaccine design processes, improving quality and dramatically reducing time and resource requirementsAI-Immunology, already superior in vaccine target discovery...
► Artikel lesen
06.10.Evaxion A/S - 6-K, Report of foreign issuer2
03.10.Evaxion to present new biomarker data for AI-designed personalized cancer vaccine EVX-01 at the SITC 2025 Annual Meeting329New biomarker and immune data from the ongoing phase 2 trial with EVX-01 will be presented at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting The data will be the latest of many additions...
► Artikel lesen
25.09.MSD pays up to nearly $600m for Evaxion's mystery vaccine candidate32
25.09.Evaxion Stock Jumps 27% On Merck Out-Licensing Deal19
25.09.Evaxion Out-licenses Vaccine Candidate EVX-B3 To Merck & Co.371KENILWORTH (NJ) (dpa-AFX) - TechBio company Evaxion A/S (EVAX) announced Thursday it has out-licensed its vaccine candidate EVX-B3 to Merck & Co., Inc. or MSD (MRK), as per the option and license...
► Artikel lesen
25.09.Evaxion A/S - 6-K, Report of foreign issuer2
25.09.Evaxion out-licenses vaccine candidate EVX-B3 to MSD391MSD exercises its option on vaccine candidate EVX-B3 for a cash payment of $7.5 million, which extend Evaxion's cash runway to first half of 2027 MSD will assume full responsibility for the further...
► Artikel lesen
25.09.MSD exercises option on Evaxion's vaccine candidate for $7.5 million17
27.08.Evaxion A/S - 6-K, Report of foreign issuer5
27.08.Evaxion to present at several conferences during the second half of 2025364Evaxion will provide scientific and company updates at numerous conferences in both the US, Europe and Asia during the coming months COPENHAGEN, Denmark, August 27, 2025 - Evaxion A/S (NASDAQ: EVAX)...
► Artikel lesen
14.08.Evaxion Biotech ADS GAAP EPS of -$0.022
14.08.Evaxion announces business update and second quarter 2025 financial results457COPENHAGEN, Denmark, August 14, 2025 - Evaxion A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology powered vaccines, provides business update and...
► Artikel lesen
13.08.Insights Ahead: Evaxion Biotech's Quarterly Earnings1
Weiter >>
74 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1